ghrp 6 is a potent growth hormone stimulating peptide that can promote muscle mass growth, fat loss and improve post-workout recovery. It also has powerful antioxidant properties that can reduce heart attack damage. Research in porcine models shows that GHRP-6 can prevent oxidant cytotoxicity by promoting intracellular phosphatidylinositol (PI) turnover and subsequently inhibiting free radical production in the damaged tissue. This may lead to the development of drugs that could be administered after a heart attack to protect the remaining viable cells and thus improve long-term outcome.
GHRP-6 directly stimulates growth and development of multiple types of cells by binding to the CD36 receptor, which is known to promote blood vessel growth, particularly in wound healing. It also increases Growth Hormone formation and secretion. It also interacts with a feedback loop to counteract the inhibition of Growth Hormone production by glucocorticoids and other inflammatory compounds.
In the case of liver fibrosis, GHRP-6 prevents the progression of HTS in animal models by decreasing the activation of NF-kB and expression of proinflammatory cytokines. Additionally, it has been shown to attenuate the differentiation of hepatocytes to myofibroblasts and decreases collagen fibrillogenesis and matrix accumulation by suppressing transcriptional activity of profibrogenic genes.
Topical administration of GHRP-6 also improves the macroscopic aspect of the wound by reducing HTS as shown by reduced &SEI and the presence of mature neovessels, which are positively labeled with anti-CD31 antibodies. Moreover, the hexapeptide significantly increases the proliferation of endothelial cells and promotes angiogenesis and vascularization in the treatment group of nonresponsive wounds compared to control.